NIHR Birmingham Biomedical Research Centre, University Hospital Birmingham and University of Birmingham, Birmingham, UK.
Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Exp Mol Med. 2024 Jul;56(7):1667-1681. doi: 10.1038/s12276-024-01287-y. Epub 2024 Jul 18.
Patients with chronic liver disease (CLD) often present with significant frailty, sarcopenia, and impaired immune function. However, the mechanisms driving the development of these age-related phenotypes are not fully understood. To determine whether accelerated biological aging may play a role in CLD, epigenetic, transcriptomic, and phenotypic assessments were performed on the skeletal muscle tissue and immune cells of CLD patients and age-matched healthy controls. Accelerated biological aging of the skeletal muscle tissue of CLD patients was detected, as evidenced by an increase in epigenetic age compared with chronological age (mean +2.2 ± 4.8 years compared with healthy controls at -3.0 ± 3.2 years, p = 0.0001). Considering disease etiology, age acceleration was significantly greater in both the alcohol-related (ArLD) (p = 0.01) and nonalcoholic fatty liver disease (NAFLD) (p = 0.0026) subgroups than in the healthy control subgroup, with no age acceleration observed in the immune-mediated subgroup or healthy control subgroup (p = 0.3). The skeletal muscle transcriptome was also enriched for genes associated with cellular senescence. Similarly, blood cell epigenetic age was significantly greater than that in control individuals, as calculated using the PhenoAge (p < 0.0001), DunedinPACE (p < 0.0001), or Hannum (p = 0.01) epigenetic clocks, with no difference using the Horvath clock. Analysis of the IMM-Age score indicated a prematurely aged immune phenotype in CLD patients that was 2-fold greater than that observed in age-matched healthy controls (p < 0.0001). These findings suggested that accelerated cellular aging may contribute to a phenotype associated with advanced age in CLD patients. Therefore, therapeutic interventions to reduce biological aging in CLD patients may improve health outcomes.
患有慢性肝病 (CLD) 的患者常表现出明显的虚弱、肌肉减少症和免疫功能受损。然而,导致这些与年龄相关表型发展的机制尚未完全阐明。为了确定加速的生物学衰老是否在 CLD 中起作用,对 CLD 患者和年龄匹配的健康对照者的骨骼肌组织和免疫细胞进行了表观遗传学、转录组学和表型评估。CLD 患者的骨骼肌组织存在加速的生物学衰老,表现在与实际年龄相比,表观遗传学年龄增加(与健康对照组相比,平均值+2.2±4.8 岁,而健康对照组为-3.0±3.2 岁,p=0.0001)。考虑到疾病病因,酒精相关(ArLD)(p=0.01)和非酒精性脂肪性肝病(NAFLD)(p=0.0026)亚组的年龄加速明显大于健康对照组亚组,而免疫介导亚组或健康对照组亚组未观察到年龄加速(p=0.3)。骨骼肌转录组也富含与细胞衰老相关的基因。同样,使用 PhenoAge(p<0.0001)、DunedinPACE(p<0.0001)或 Hannum(p=0.01)表观遗传时钟计算时,血细胞表观遗传学年龄明显大于对照组,而使用 Horvath 时钟时则无差异(p<0.0001)。对 IMM-Age 评分的分析表明,CLD 患者的免疫表型过早衰老,比年龄匹配的健康对照者高 2 倍(p<0.0001)。这些发现表明,加速的细胞衰老可能导致 CLD 患者与年龄相关的表型。因此,减少 CLD 患者生物学衰老的治疗干预可能改善健康结局。